Published in Arthritis Rheum on August 01, 1990
Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL) (TABUL) | NCT00974883
Validation of a Diagnostic Algorithm of Giant Cell Arteritis (ECHORTON) | NCT02703922
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum (2008) 19.80
Aortitis. Circulation (2008) 3.60
Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med (2014) 3.46
Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med (2014) 2.76
Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum (2011) 2.31
The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum (2011) 1.91
Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis (2006) 1.91
New features of disease after diagnosis in 6 forms of systemic vasculitis. J Rheumatol (2013) 1.59
Diagnostic performance of ¹⁸F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging (2011) 1.55
Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest (1996) 1.54
Systematic review of the literature and a case report informing biopsy-proven giant cell arteritis (GCA) with normal C-reactive protein. Clin Rheumatol (2012) 1.52
Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann Rheum Dis (2001) 1.50
Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis (2002) 1.48
The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging (2005) 1.47
Diagnosis and treatment of cerebral vasculitis. Ther Adv Neurol Disord (2010) 1.47
Extra- and intracranial cerebral vasculitis in giant cell arteritis: an observational study. Medicine (Baltimore) (2014) 1.42
Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol (1999) 1.41
Trends in the clinical presentation of temporal arteritis in Israel: reflection of increased physician awareness. Clin Rheumatol (1996) 1.40
Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. J Clin Invest (1994) 1.26
A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging (2006) 1.24
Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis (2012) 1.23
A new international classification of childhood vasculitis. Pediatr Nephrol (2006) 1.22
Review of Giant cell arteritis. Saudi J Ophthalmol (2014) 1.20
Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clin Rheumatol (2010) 1.19
Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol (2012) 1.18
Giant cell arteritis or tension-type headache?: A differential diagnostic dilemma. J Neurosci Rural Pract (2014) 1.14
Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol (1996) 1.13
Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Res Ther (2006) 1.13
The use of (18)F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol (2013) 1.13
18F-FDG PET as a diagnostic procedure in large vessel vasculitis-a controlled, blinded re-examination of routine PET scans. Clin Rheumatol (2010) 1.12
Biopsy-negative, varicella zoster virus (VZV)-positive giant cell arteritis, zoster, VZV encephalitis and ischemic optic neuropathy, all in one. J Neurol Sci (2014) 1.12
[Temporal arteritis (giant cell arteritis). Clinical picture, histology, and treatment]. Ophthalmologe (2006) 1.12
Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. Clin Rheumatol (2011) 1.11
The importance of skip lesions in temporal arteritis. J Clin Pathol (2000) 1.09
The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest (1998) 1.08
Insights into imaging of aortitis. Insights Imaging (2012) 1.08
Clinicopathologic correlations in giant cell arteritis: a retrospective study of 107 cases. Ophthalmology (2009) 1.08
The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord (2010) 1.07
Decorin is produced by capillary endothelial cells in inflammation-associated angiogenesis. Am J Pathol (2001) 1.06
Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res Ther (2006) 1.03
Neurology of the vasculitides and connective tissue diseases. J Neurol Neurosurg Psychiatry (1998) 1.03
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. Am J Hum Genet (2015) 1.02
Isolated vasculitis of the female genital tract: a case series and review of literature. Virchows Arch (2007) 1.02
The role of 18F-FDG PET/CT in large-vessel vasculitis: appropriateness of current classification criteria? Biomed Res Int (2014) 1.01
Temporal artery biopsy...who needs one? Postgrad Med J (2006) 1.00
Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry (2007) 1.00
Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis (1996) 0.99
Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol (2002) 0.99
Dry cough is a frequent manifestation of giant cell arteritis. Rheumatol Int (2012) 0.98
Statin use in giant cell arteritis: a retrospective study. J Rheumatol (2013) 0.98
Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis. Ann Rheum Dis (2013) 0.98
Nomenclature and classification of vasculitis - update on the ACR/EULAR diagnosis and classification of vasculitis study (DCVAS). Clin Exp Immunol (2011) 0.98
The diagnosis and treatment of giant cell arteritis. Dtsch Arztebl Int (2013) 0.97
Giant cell arteritis. Rheumatol Int (2008) 0.97
An atypical presentation of giant cell arteritis. CMAJ (2011) 0.97
Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol (2013) 0.96
Vasculitis in systemic sclerosis. Int J Rheumatol (2010) 0.96
Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol (1998) 0.95
Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology. Histochem Cell Biol (2006) 0.95
Malignancy risk in patients with giant cell arteritis: a population-based cohort study. Arthritis Care Res (Hoboken) (2010) 0.94
The prognostic value of baseline (18)F-FDG PET/CT in steroid-naïve large-vessel vasculitis: introduction of volume-based parameters. Eur J Nucl Med Mol Imaging (2015) 0.92
Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography. Biomed Res Int (2014) 0.92
Balloon angioplasty of arteries of the upper extremities in patients with extracranial giant-cell arteritis. Ann Rheum Dis (2006) 0.92
Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach. Arthritis Res Ther (2011) 0.90
18F-Fludeoxyglucose PET/CT in the evaluation of large-vessel vasculitis: diagnostic performance and correlation with clinical and laboratory parameters. Br J Radiol (2011) 0.90
Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l'Artérite à Cellules Géantes. Ann Rheum Dis (1999) 0.90
Spontaneous bilateral necrosis of the tongue: a manifestation of giant cell arteritis? Eur Arch Otorhinolaryngol (2008) 0.90
Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides. Clin Rheumatol (2006) 0.90
Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis. Ophthalmology (2016) 0.89
Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study. Arthritis Res Ther (2009) 0.88
Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis (2011) 0.88
Non-infectious orbital vasculitides. Eye (Lond) (2012) 0.88
The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950-2009. Scand J Rheumatol (2015) 0.87
Color duplex ultrasonography of temporal arteries: role in diagnosis and follow-up of suspected cases of temporal arteritis. Clin Rheumatol (2011) 0.87
Characteristics of cerebrovascular accidents at time of diagnosis in a series of 98 patients with giant cell arteritis. Rheumatol Int (2013) 0.86
Standardised work-up programme for fever of unknown origin and contribution of magnetic resonance imaging for the diagnosis of hidden systemic vasculitis. Ann Rheum Dis (2005) 0.86
Fatal aortic dissection in a patient with giant cell arteritis: a case report and review of the literature. Case Rep Vasc Med (2013) 0.86
CT and MRI in the Evaluation of Thoracic Aortic Diseases. Int J Vasc Med (2013) 0.86
Influence of corticosteroid treatment on MRI findings in giant cell arteritis. Clin Rheumatol (2006) 0.86
Varicella Zoster Virus Infection in Granulomatous Arteritis of the Aorta. J Infect Dis (2016) 0.85
Anterior ischemic optic neuropathy due to giant cell arteritis with normal inflammatory markers. Graefes Arch Clin Exp Ophthalmol (2008) 0.85
Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study. Rheumatology (Oxford) (2010) 0.85
Magnetic resonance angiography in extracranial giant cell arteritis. J Clin Rheumatol (2011) 0.85
Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis. J Rheumatol (2011) 0.85
Giant cell arteritis. Postgrad Med J (2003) 0.85
Imaging large vessel vasculitis with fully integrated PET/MRI: a pilot study. Eur J Nucl Med Mol Imaging (2015) 0.84
Towards an optimal semiquantitative approach in giant cell arteritis: an (18)F-FDG PET/CT case-control study. Eur J Nucl Med Mol Imaging (2013) 0.84
Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford) (2014) 0.84
Relationship between histological subtypes and clinical characteristics at presentation and outcome in biopsy-proven temporal arteritis. Identification of a relatively benign subgroup. Clin Rheumatol (2006) 0.84
3-T MRI reveals cranial and thoracic inflammatory changes in giant cell arteritis. Clin Rheumatol (2006) 0.84
A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol (2017) 0.83
Body mass index and the risk of giant cell arteritis: results from a prospective study. Rheumatology (Oxford) (2014) 0.83
Color-coded sonography in suspected temporal arteritis-experiences after 83 cases. Rheumatol Int (2003) 0.83
Temporal arteritis: improving patient evaluation with a new protocol. Perm J (2013) 0.83
Large vessel vasculitis in elderly patients: early diagnosis and steroid-response evaluation with FDG-PET/CT and contrast-enhanced CT. Rheumatol Int (2014) 0.82
Cancer preceding giant cell arteritis: a case-control study. Arthritis Rheum (2010) 0.82
Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population-based retrospective cohort study. Arthritis Care Res (Hoboken) (2015) 0.82
Peroxiredoxin 2 is a novel autoantigen for anti-endothelial cell antibodies in systemic vasculitis. Clin Exp Immunol (2010) 0.82
Non-invasive imaging of vascular inflammation. Front Immunol (2014) 0.81
Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy. Br J Ophthalmol (1999) 0.81
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (1993) 15.54
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med (1992) 13.29
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med (1986) 9.86
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum (1990) 8.92
The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum (1990) 8.67
The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum (1990) 8.36
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med (1983) 8.26
The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science (1989) 7.90
Toward an understanding of the correlates of protective immunity to HIV infection. Science (1996) 7.59
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med (1978) 7.17
Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med (1986) 6.52
Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med (1985) 6.46
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A (1989) 6.32
Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A (1989) 6.32
The mortality of rheumatoid arthritis. Arthritis Rheum (1994) 6.18
Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol (1989) 6.02
Takayasu arteritis. Ann Intern Med (1994) 5.94
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature (1990) 5.86
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med (1993) 5.32
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol (1986) 5.19
Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med (1976) 5.16
The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum (1990) 5.09
Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J Virol (1986) 5.05
Two-dimensional real-time ultrasonic imaging of the heart and great vessels. Technique, image orientation, structure identification, and validation. Mayo Clin Proc (1978) 4.92
The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest (1974) 4.90
Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) (1973) 4.89
Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature (1990) 4.87
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Human immunodeficiency virus infection among patients attending clinics for sexually transmitted diseases. N Engl J Med (1988) 4.81
Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A (1990) 4.80
A simple method of sample size calculation for linear and logistic regression. Stat Med (1998) 4.74
Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med (1996) 4.72
NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med (1982) 4.70
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum (1990) 4.43
Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 4.23
HIV. An elusive soluble suppressor. Nature (1995) 4.18
Capturing the patient's view of change as a clinical outcome measure. JAMA (1999) 4.11
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science (1986) 3.80
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol (1997) 3.77
Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology (1989) 3.60
Re-emergence of HIV after stopping therapy. Nature (1999) 3.54
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (1990) 3.50
Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol (1988) 3.45
Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science (1989) 3.43
Thoracic aortic aneurysms: a population-based study. Surgery (1982) 3.36
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood (1988) 3.30
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29
Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage (1996) 3.26
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20